Luiz R Travassos
Overview
Explore the profile of Luiz R Travassos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
2263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oliveira J, Lacerda J, Sellani T, Rodrigues E, Travassos L, Juliano M, et al.
Biochemistry
. 2024 Aug;
63(16):2023-2029.
PMID: 39106042
The kallikrein-related peptidase KLK2 has restricted expression in the prostate luminal epithelium, and its protein target is unknown. The present work reports the hydrolytic activities of KLK2 on libraries of...
2.
Maia V, Berzaghi R, Arruda D, Machado F, Loureiro L, Melo P, et al.
Sci Rep
. 2022 Feb;
12(1):2890.
PMID: 35190586
Malignant melanoma is the main cause of death in patients with skin cancer. Overexpression of Proteolipid protein 2 (PLP2) increased tumor metastasis and the knockdown of PLP2 inhibited the growth...
3.
de Oliveira T, Travassos L, Arruda D, Tada D
J Biomed Nanotechnol
. 2021 Aug;
17(7):1320-1329.
PMID: 34446135
Nanoparticles (NPs) are a promising strategy for delivering drugs to specific sites because of their tunable size and surface chemistry variety. Among the availablematerials, NPs prepared with biopolymers are of...
4.
de Azevedo R, Shoshan E, Whang S, Markel G, Jaiswal A, Liu A, et al.
Oncoimmunology
. 2020 Dec;
9(1):1846915.
PMID: 33344042
Immune checkpoint blockade (ICB) has demonstrated an impressive outcome in patients with metastatic melanoma, yet, durable complete response; even with Ipilimumab/Nivolumab combo are under 30%. Primary and acquired resistance in...
5.
Kischkel B, Rossi S, Santos S, Nosanchuk J, Travassos L, Taborda C
Front Cell Infect Microbiol
. 2020 Oct;
10:463.
PMID: 33014889
Treatment modalities for systemic mycoses are still limited. Currently, the main antifungal therapeutics include polyenes, azoles, and echinocandins. However, even in the setting of appropriate administration of antifungals, mortality rates...
6.
Rodrigues Dos Santos Junior S, da Silva F, Santos Dias L, Souza A, Araujo M, da Silva L, et al.
J Fungi (Basel)
. 2020 Sep;
6(3).
PMID: 32887256
Paracoccidioidomycosis (PCM) is a granulomatous fungal disease caused by the dimorphic fungal species of , which mainly affects the lungs. Modern strategies for the treatment and/or prevention of PCM are...
7.
Boniche C, Rossi S, Kischkel B, Barbalho F, Moura A, Nosanchuk J, et al.
J Fungi (Basel)
. 2020 Mar;
6(1).
PMID: 32121415
The increasing incidence in systemic fungal infections in humans has increased focus for the development of fungal vaccines and use of monoclonal antibodies. Invasive mycoses are generally difficult to treat,...
8.
Machado F, Girola N, Maia V, Bergami-Santos P, Morais A, Azevedo R, et al.
Front Immunol
. 2020 Feb;
10:3122.
PMID: 32010152
The cyclic VHCDR3-derived peptide (Rb9) from RebMab200 antibody, directed to a NaPi2B phosphate-transport protein, displayed anti-metastatic melanoma activity at 50-300 μg intraperitoneally injected in syngeneic mice. Immune deficient mice failed...
9.
Silva L, Taira C, S Dias L, Souza A, Nosanchuk J, Travassos L, et al.
Front Microbiol
. 2019 Aug;
10:1727.
PMID: 31417520
Paracoccidioidomycosis (PCM) is an endemic mycosis in Latin American caused by the thermodimorphic fungi of the genus spp. Notably, a Th1 immune response is required to control PCM. In this...
10.
Paschoalin T, Martens A, Omori A, Pereira F, Juliano L, Travassos L, et al.
Bioorg Med Chem
. 2019 Apr;
27(12):2537-2545.
PMID: 30962115
Protease roles in cancer progression have been demonstrated and their inhibitors display antitumor effects. Cathepsins are lysosomal cysteine proteases that have increased expression in tumor cells, and tellurium compounds were...